Non-Hodgkin Lymphoma - Pipeline Review, H2 2017

Date: November 28, 2017
Pages: 1990
Price:
US$ 2,500.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: N84ACA70EB6EN
Leaflet:

Download PDF Leaflet

Non-Hodgkin Lymphoma - Pipeline Review, H2 2017
Non-Hodgkin Lymphoma - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Hodgkin Lymphoma - Pipeline Review, H2 2017, provides an overview of the Non-Hodgkin Lymphoma (Oncology) pipeline landscape.

Non-Hodgkin lymphoma (also known as non-Hodgkin’s lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts in cells called lymphocytes, which are part of the body’s immune system. Symptoms depend on what area of the body is affected by the cancer and how fast the cancer is growing. Symptoms may include night sweats (soaking the bed sheets and pajamas even though the room temperature is not too hot),fever and chills that come and go, itching, swollen lymph nodes in the neck, underarms, groin, or other areas, weight loss, coughing or shortness of breath if the cancer affects the thymus gland or lymph nodes in the chest, putting pressure on the windpipe (trachea) or other airway, abdominal pain or swelling, leading to loss of appetite, constipation, nausea, and vomiting and headache, concentration problems, personality changes, or seizures if the cancer affects the brain. Treatment includes surgery, radiation therapy and chemotherapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Non-Hodgkin Lymphoma - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Non-Hodgkin Lymphoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Non-Hodgkin Lymphoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Non-Hodgkin Lymphoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 8, 2, 27, 142, 143, 1, 8, 117, 17 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 18, 20, 16 and 4 molecules, respectively.

Non-Hodgkin Lymphoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Hodgkin Lymphoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Non-Hodgkin Lymphoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Non-Hodgkin Lymphoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Non-Hodgkin Lymphoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Non-Hodgkin Lymphoma (Oncology)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Non-Hodgkin Lymphoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Non-Hodgkin Lymphoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Non-Hodgkin Lymphoma - Overview
Non-Hodgkin Lymphoma - Therapeutics Development
Non-Hodgkin Lymphoma - Therapeutics Assessment
Non-Hodgkin Lymphoma - Companies Involved in Therapeutics Development
Non-Hodgkin Lymphoma - Drug Profiles
Non-Hodgkin Lymphoma - Dormant Projects 1899
Non-Hodgkin Lymphoma - Discontinued Products 1921
Non-Hodgkin Lymphoma - Product Development Milestones 1929
Appendix 1939

LIST OF TABLES

Number of Products under Development for Non-Hodgkin Lymphoma, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.4), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.5), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.6), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.7), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.8), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.9), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.10), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.11), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.12), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.13), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd.2), H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Products under Development by Companies, H2 2017 (Contd.4), H2 2017
Products under Development by Companies, H2 2017 (Contd.5), H2 2017
Products under Development by Companies, H2 2017 (Contd.6), H2 2017
Products under Development by Companies, H2 2017 (Contd.7), H2 2017
Products under Development by Companies, H2 2017 (Contd.8), H2 2017
Products under Development by Companies, H2 2017 (Contd.9), H2 2017
Products under Development by Companies, H2 2017 (Contd.10), H2 2017
Products under Development by Companies, H2 2017 (Contd.11), H2 2017
Products under Development by Companies, H2 2017 (Contd.12), H2 2017
Products under Development by Companies, H2 2017 (Contd.13), H2 2017
Products under Development by Companies, H2 2017 (Contd.14), H2 2017
Products under Development by Companies, H2 2017 (Contd.15), H2 2017
Products under Development by Companies, H2 2017 (Contd.16), H2 2017
Products under Development by Companies, H2 2017 (Contd.17), H2 2017
Products under Development by Companies, H2 2017 (Contd.18), H2 2017
Products under Development by Companies, H2 2017 (Contd.19), H2 2017
Products under Development by Companies, H2 2017 (Contd.20), H2 2017
Products under Development by Companies, H2 2017 (Contd.21), H2 2017
Products under Development by Companies, H2 2017 (Contd.22), H2 2017
Products under Development by Companies, H2 2017 (Contd.23), H2 2017
Products under Development by Companies, H2 2017 (Contd.24), H2 2017
Products under Development by Companies, H2 2017 (Contd.25), H2 2017
Products under Development by Companies, H2 2017 (Contd.26), H2 2017
Products under Development by Companies, H2 2017 (Contd.27), H2 2017
Products under Development by Companies, H2 2017 (Contd.28), H2 2017
Products under Development by Companies, H2 2017 (Contd.29), H2 2017
Products under Development by Companies, H2 2017 (Contd.30), H2 2017
Products under Development by Companies, H2 2017 (Contd.31), H2 2017
Products under Development by Companies, H2 2017 (Contd.32), H2 2017
Products under Development by Companies, H2 2017 (Contd.33), H2 2017
Products under Development by Companies, H2 2017 (Contd.34), H2 2017
Products under Development by Companies, H2 2017 (Contd.35), H2 2017
Products under Development by Companies, H2 2017 (Contd.36), H2 2017
Products under Development by Companies, H2 2017 (Contd.37), H2 2017
Products under Development by Companies, H2 2017 (Contd.38), H2 2017
Products under Development by Companies, H2 2017 (Contd.39), H2 2017
Products under Development by Companies, H2 2017 (Contd.40), H2 2017
Products under Development by Companies, H2 2017 (Contd.41), H2 2017
Products under Development by Companies, H2 2017 (Contd.42), H2 2017
Products under Development by Companies, H2 2017 (Contd.43), H2 2017
Products under Development by Companies, H2 2017 (Contd.44), H2 2017
Products under Development by Companies, H2 2017 (Contd.45), H2 2017
Products under Development by Companies, H2 2017 (Contd.46), H2 2017
Products under Development by Companies, H2 2017 (Contd.47), H2 2017
Products under Development by Companies, H2 2017 (Contd.48), H2 2017
Products under Development by Companies, H2 2017 (Contd.49), H2 2017
Products under Development by Companies, H2 2017 (Contd.50), H2 2017
Products under Development by Companies, H2 2017 (Contd.51), H2 2017
Products under Development by Companies, H2 2017 (Contd.52), H2 2017
Products under Development by Companies, H2 2017 (Contd.53), H2 2017
Products under Development by Universities/Institutes, H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd.1), H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd.2), H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd.3), H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd.4), H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.2), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.3), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.4), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.5), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.6), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.7), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.8), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.9), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.2), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.3), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.4), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.5), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.6), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.7), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.8), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.9), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Non-Hodgkin Lymphoma - Pipeline by 3SBio Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by 4SC AG, H2 2017
Non-Hodgkin Lymphoma - Pipeline by AB Science SA, H2 2017
Non-Hodgkin Lymphoma - Pipeline by AbbVie Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by ACEA Biosciences Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Actinium Pharmaceuticals Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by ADC Therapeutics Sarl, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Affimed GmbH, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Affitech A/S, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Aileron Therapeutics Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Allinky Biopharma, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Altor BioScience Corp, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Amgen Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Angimmune LLC, H2 2017
Non-Hodgkin Lymphoma - Pipeline by arGEN-X BV, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Ariad Pharmaceuticals Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Arno Therapeutics Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by ArQule Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Arrien Pharmaceuticals LLC, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Arven Ilac, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Asana BioSciences LLC, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Astellas Pharma Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Astex Pharmaceuticals Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by AstraZeneca Plc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Aurigene Discovery Technologies Ltd, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Autolus Ltd, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Bantam Pharmaceutical LLC, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Bayer AG, H2 2017
Non-Hodgkin Lymphoma - Pipeline by BeiGene Ltd, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Bellicum Pharmaceuticals Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Bio-Path Holdings Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by BioAtla LLC, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Biocon Ltd, H2 2017
Non-Hodgkin Lymphoma - Pipeline by BioInvent International AB, H2 2017
Non-Hodgkin Lymphoma - Pipeline by BioLineRx Ltd, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Bionovis SA, H2 2017
Non-Hodgkin Lymphoma - Pipeline by BioSight Ltd, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Biothera Pharmaceutical Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Boston Biomedical Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Bristol-Myers Squibb Co, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Calithera Biosciences Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Cascadian Therapeutics Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Celgene Corp, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Cell Medica Ltd, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Cell Source Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Cell>Point LLC, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Celldex Therapeutics Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Cellectar Biosciences Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Cellectis SA, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Celleron Therapeutics Ltd, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Celltrion Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Cellular Biomedicine Group Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Celon Pharma SA, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Centrose LLC, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Cerenis Therapeutics Holding SA, H2 2017
Non-Hodgkin Lymphoma - Pipeline by CerRx Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Chipscreen Biosciences Ltd, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Clevexel Pharma SAS, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Coherus BioSciences Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by CrystalGenomics Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by CSPC Pharmaceutical Group Limited, H2 2017
Non-Hodgkin Lymphoma - Pipeline by CTI BioPharma Corp, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Curis Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by CytomX Therapeutics Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Daiichi Sankyo Co Ltd, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Debiopharm International SA, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Denovo Biopharma LLC, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Dynavax Technologies Corp, H2 2017
Non-Hodgkin Lymphoma - Pipeline by eFFECTOR Therapeutics Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Eisai Co Ltd, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Eli Lilly and Co, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Epizyme Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Erytech Pharma SA, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Evotec AG, H2 2017
Non-Hodgkin Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Forma Therapeutics Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Formula Pharmaceuticals Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Forty Seven Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Galderma SA, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Genentech Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Genor BioPharma Co Ltd, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Genosco Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Gilead Sciences Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by GlaxoSmithKline Plc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Grupo Ferrer Internacional SA, H2 2017
Non-Hodgkin Lymphoma - Pipeline by GT Biopharma Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by H3 Biomedicine Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Heidelberg Pharma GmbH, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Humorigin Biotechnology Corp, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Hutchison MediPharma Ltd, H2 2017
Non-Hodgkin Lymphoma - Pipeline by iDD biotech SAS, H2 2017
Non-Hodgkin Lymphoma - Pipeline by IGF Oncology LLC, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Ignyta Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Immune Design Corp, H2 2017
Non-Hodgkin Lymphoma - Pipeline by ImmunGene Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by ImmunoGen Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Immunomedics Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Immunovaccine Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Incyte Corp, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Inflection Biosciences Ltd, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Innate Pharma SA, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Innovent Biologics Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Japan Tobacco Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by JHL Biotech Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Johnson & Johnson, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Juno Therapeutics Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by K-Stemcell Co Ltd, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Kainos Medicine Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Karyopharm Therapeutics Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Kite Pharma Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Klyss Biotech Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Komipharm International Co Ltd, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Leadiant Biosciences Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Les Laboratoires Servier SAS, H2 2017
Non-Hodgkin Lymphoma - Pipeline by LFB SA, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Loxo Oncology Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by LSK BioPartners Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Mabion SA, H2 2017
Non-Hodgkin Lymphoma - Pipeline by MacroGenics Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Meabco AS, H2 2017
Non-Hodgkin Lymphoma - Pipeline by MedImmune LLC, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Medivir AB, H2 2017
Non-Hodgkin Lymphoma - Pipeline by MEI Pharma Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by MENTRIK Biotech LLC, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Merck & Co Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Merck KGaA, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Miltenyi Biotec GmbH, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Miragen Therapeutics Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Mirati Therapeutics Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Molecular Templates Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Moleculin Biotech Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Morphogenesis Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by MorphoSys AG, H2 2017
Non-Hodgkin Lymphoma - Pipeline by NantKwest Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by NBE-Therapeutics AG, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Neumedicines Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Nichi-Iko Pharmaceutical Co Ltd, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Nordic Nanovector ASA, H2 2017
Non-Hodgkin Lymphoma - Pipeline by NovaLead Pharma Pvt Ltd, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Novartis AG, H2 2017
Non-Hodgkin Lymphoma - Pipeline by NovImmune SA, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Oncobiologics Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Onconova Therapeutics Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Oncopeptides AB, H2 2017
Non-Hodgkin Lymphoma - Pipeline by OncoSec Medical Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Oncovir Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Oncternal Therapeutics Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Onxeo SA, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Oxford BioTherapeutics Ltd, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Patrys Ltd, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Pfizer Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Pharma Mar SA, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Philogen SpA, H2 2017
Non-Hodgkin Lymphoma - Pipeline by PIQUR Therapeutics AG, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Plexxikon Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Polaris Pharmaceuticals Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Portola Pharmaceuticals Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Prescient Therapeutics Ltd, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Rafael Pharmaceuticals Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by RedHill Biopharma Ltd, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Regeneron Pharmaceuticals Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Respiratorius AB, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Rhizen Pharmaceuticals SA, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Richter Gedeon Nyrt, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Sandoz International GmbH, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Sanofi, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Sareum Holdings Plc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Seattle Genetics Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Selvita SA, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Senhwa Biosciences Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Shanghai Pharmaceutical Co Ltd, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Shenzhen Salubris Pharmaceuticals Co Ltd, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Sierra Oncology Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Sigma-Tau SpA, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Solasia Pharma KK, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Soligenix Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Sorrento Therapeutics Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Spectrum Pharmaceuticals Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Stemline Therapeutics Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Sunesis Pharmaceuticals Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Supratek Pharma Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Surface Oncology Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Sutro Biopharma Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Syndax Pharmaceuticals Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Taiwan Liposome Company Ltd, H2 2017
Non-Hodgkin Lymphoma - Pipeline by TC BioPharm Ltd, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2017
Non-Hodgkin Lymphoma - Pipeline by TG Therapeutics Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by TRACON Pharmaceuticals Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Transgene Biotek Ltd, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Transgene SA, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Trillium Therapeutics Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Trovagene Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by TTY Biopharm Company Ltd, H2 2017
Non-Hodgkin Lymphoma - Pipeline by United BioPharma Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Unum Therapeutics Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Verastem Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Vivolux AB, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Vyriad Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Xencor Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by Xenetic Biosciences Inc, H2 2017
Non-Hodgkin Lymphoma - Pipeline by ZIOPHARM Oncology Inc, H2 2017
Non-Hodgkin Lymphoma - Dormant Projects, H2 2017 1949
Non-Hodgkin Lymphoma - Dormant Projects, H2 2017 (Contd.1), H2 2017 1950
Non-Hodgkin Lymphoma - Dormant Projects, H2 2017 (Contd.2), H2 2017 1951
Non-Hodgkin Lymphoma - Dormant Projects, H2 2017 (Contd.3), H2 2017 1952
Non-Hodgkin Lymphoma - Dormant Projects, H2 2017 (Contd.4), H2 2017 1953
Non-Hodgkin Lymphoma - Dormant Projects, H2 2017 (Contd.5), H2 2017 1954
Non-Hodgkin Lymphoma - Dormant Projects, H2 2017 (Contd.6), H2 2017 1956
Non-Hodgkin Lymphoma - Dormant Projects, H2 2017 (Contd.7), H2 2017 1957
Non-Hodgkin Lymphoma - Dormant Projects, H2 2017 (Contd.8), H2 2017 1958
Non-Hodgkin Lymphoma - Dormant Projects, H2 2017 (Contd.9), H2 2017 1959
Non-Hodgkin Lymphoma - Dormant Projects, H2 2017 (Contd.10), H2 2017 1960
Non-Hodgkin Lymphoma - Dormant Projects, H2 2017 (Contd.11), H2 2017 1961
Non-Hodgkin Lymphoma - Dormant Projects, H2 2017 (Contd.12), H2 2017 1962
Non-Hodgkin Lymphoma - Dormant Projects, H2 2017 (Contd.13), H2 2017 1963
Non-Hodgkin Lymphoma - Dormant Projects, H2 2017 (Contd.14), H2 2017 1964
Non-Hodgkin Lymphoma - Dormant Projects, H2 2017 (Contd.15), H2 2017 1965
Non-Hodgkin Lymphoma - Dormant Projects, H2 2017 (Contd.16), H2 2017 1966
Non-Hodgkin Lymphoma - Dormant Projects, H2 2017 (Contd.17), H2 2017 1967
Non-Hodgkin Lymphoma - Dormant Projects, H2 2017 (Contd.18), H2 2017 1968
Non-Hodgkin Lymphoma - Dormant Projects, H2 2017 (Contd.19), H2 2017 1969
Non-Hodgkin Lymphoma - Dormant Projects, H2 2017 (Contd.20), H2 2017 1970
Non-Hodgkin Lymphoma - Discontinued Products, H2 2017 1971
Non-Hodgkin Lymphoma - Discontinued Products, H2 2017 (Contd.1), H2 2017 1972
Non-Hodgkin Lymphoma - Discontinued Products, H2 2017 (Contd.2), H2 2017 1973
Non-Hodgkin Lymphoma - Discontinued Products, H2 2017 (Contd.3), H2 2017 1974
Non-Hodgkin Lymphoma - Discontinued Products, H2 2017 (Contd.4), H2 2017 1975
Non-Hodgkin Lymphoma - Discontinued Products, H2 2017 (Contd.5), H2 2017 1976
Non-Hodgkin Lymphoma - Discontinued Products, H2 2017 (Contd.6), H2 2017 1977
Non-Hodgkin Lymphoma - Discontinued Products, H2 2017 (Contd.7), H2 2017 1978

LIST OF FIGURES

Number of Products under Development for Non-Hodgkin Lymphoma, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

COMPANIES MENTIONED

3SBio Inc
4SC AG
AB Science SA
AbbVie Inc
ACEA Biosciences Inc
Actinium Pharmaceuticals Inc
ADC Therapeutics Sarl
Affimed GmbH
Affitech A/S
Aileron Therapeutics Inc
Allinky Biopharma
Altor BioScience Corp
Amgen Inc
Angimmune LLC
arGEN-X BV
Ariad Pharmaceuticals Inc
Arno Therapeutics Inc
ArQule Inc
Arrien Pharmaceuticals LLC
Arven Ilac
Asana BioSciences LLC
Astellas Pharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Aurigene Discovery Technologies Ltd
Autolus Ltd
Bantam Pharmaceutical LLC
Bayer AG
BeiGene Ltd
Bellicum Pharmaceuticals Inc
Bio-Path Holdings Inc
BioAtla LLC
Biocon Ltd
BioInvent International AB
BioLineRx Ltd
Bionovis SA
BioSight Ltd
Biothera Pharmaceutical Inc
Boehringer Ingelheim GmbH
Boston Biomedical Inc
Bristol-Myers Squibb Co
Calithera Biosciences Inc
Cascadian Therapeutics Inc
Celgene Corp
Cell Medica Ltd
Cell Source Inc
Cell>Point LLC
Celldex Therapeutics Inc
Cellectar Biosciences Inc
Cellectis SA
Celleron Therapeutics Ltd
Celltrion Inc
Cellular Biomedicine Group Inc
Celon Pharma SA
Centrose LLC
Cerenis Therapeutics Holding SA
CerRx Inc
Chipscreen Biosciences Ltd
Clevexel Pharma SAS
Coherus BioSciences Inc
CrystalGenomics Inc
CSPC Pharmaceutical Group Limited
CTI BioPharma Corp
Curis Inc
Cyclacel Pharmaceuticals Inc
CytomX Therapeutics Inc
Daiichi Sankyo Co Ltd
Debiopharm International SA
Denovo Biopharma LLC
Dynavax Technologies Corp
eFFECTOR Therapeutics Inc
Eisai Co Ltd
Eli Lilly and Co
Epizyme Inc
Erytech Pharma SA
Evotec AG
F. Hoffmann-La Roche Ltd
Forma Therapeutics Inc
Formula Pharmaceuticals Inc
Forty Seven Inc
Galderma SA
Genentech Inc
Genor BioPharma Co Ltd
Genosco Inc
Gilead Sciences Inc
GlaxoSmithKline Plc
Grupo Ferrer Internacional SA
GT Biopharma Inc
H3 Biomedicine Inc
Heidelberg Pharma GmbH
Humorigin Biotechnology Corp
Hutchison MediPharma Ltd
iDD biotech SAS
IGF Oncology LLC
Ignyta Inc
Immune Design Corp
ImmunGene Inc
ImmunoGen Inc
Immunomedics Inc
Immunovaccine Inc
Incyte Corp
Inflection Biosciences Ltd
Innate Pharma SA
Innovent Biologics Inc
Japan Tobacco Inc
JHL Biotech Inc
Johnson & Johnson
Juno Therapeutics Inc
K-Stemcell Co Ltd
Kainos Medicine Inc
Karyopharm Therapeutics Inc
Kite Pharma Inc
Klyss Biotech Inc
Komipharm International Co Ltd
Kyowa Hakko Kirin Co Ltd
Leadiant Biosciences Inc
Les Laboratoires Servier SAS
LFB SA
Loxo Oncology Inc
LSK BioPartners Inc
Mabion SA
MacroGenics Inc
Meabco AS
MedImmune LLC
Medivir AB
MEI Pharma Inc
MENTRIK Biotech LLC
Merck & Co Inc
Merck KGaA
Millennium Pharmaceuticals Inc
Miltenyi Biotec GmbH
Miragen Therapeutics Inc
Mirati Therapeutics Inc
Molecular Templates Inc
Moleculin Biotech Inc
Morphogenesis Inc
MorphoSys AG
NantKwest Inc
NBE-Therapeutics AG
Neumedicines Inc
Nichi-Iko Pharmaceutical Co Ltd
Nordic Nanovector ASA
NovaLead Pharma Pvt Ltd
Novartis AG
NovImmune SA
Oncobiologics Inc
Onconova Therapeutics Inc
Oncopeptides AB
OncoSec Medical Inc
Oncovir Inc
Oncternal Therapeutics Inc
Ono Pharmaceutical Co Ltd
Onxeo SA
Oxford BioTherapeutics Ltd
Patrys Ltd
Pfizer Inc
Pharma Mar SA
Philogen SpA
PIQUR Therapeutics AG
Plexxikon Inc
Polaris Pharmaceuticals Inc
Portola Pharmaceuticals Inc
Prescient Therapeutics Ltd
Rafael Pharmaceuticals Inc
RedHill Biopharma Ltd
Regeneron Pharmaceuticals Inc
Respiratorius AB
Rhizen Pharmaceuticals SA
Richter Gedeon Nyrt
Sandoz International GmbH
Sanofi
Sareum Holdings Plc
Seattle Genetics Inc
Selvita SA
Senhwa Biosciences Inc
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shanghai Pharmaceutical Co Ltd
Shenzhen Salubris Pharmaceuticals Co Ltd
Sierra Oncology Inc
Sigma-Tau SpA
Solasia Pharma KK
Soligenix Inc
Sorrento Therapeutics Inc
Spectrum Pharmaceuticals Inc
Stemline Therapeutics Inc
Sunesis Pharmaceuticals Inc
Supratek Pharma Inc
Surface Oncology Inc
Sutro Biopharma Inc
Syndax Pharmaceuticals Inc
Taiho Pharmaceutical Co Ltd
Taiwan Liposome Company Ltd
TC BioPharm Ltd
Teva Pharmaceutical Industries Ltd
TG Therapeutics Inc
TRACON Pharmaceuticals Inc
Transgene Biotek Ltd
Transgene SA
Trillium Therapeutics Inc
Trovagene Inc
TTY Biopharm Company Ltd
United BioPharma Inc
Unum Therapeutics Inc
Verastem Inc
Vivolux AB
Vyriad Inc
Xencor Inc
Xenetic Biosciences Inc
ZIOPHARM Oncology Inc
Skip to top


Cancer Non-Hodgkin Lymphoma Therapy Area Pipeline Report US$ 1,495.00 Jan, 2010 · 701 pages
Non-Hodgkin Lymphoma Therapy Area Pipeline Report US$ 1,495.00 Sep, 2010 · 588 pages

Ask Your Question

Non-Hodgkin Lymphoma - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: